YAP1 and cancer: In a model of circulating cancer cells, YAP has been shown to transcriptionally activate ARHGAP29, an inhibitor of RhoA, thereby reducing the rigidity of the cytoskeleton network by escalating G- and F-actin turnover (Qiao et al., 2017).